HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation

Introduction and objectives Breast cancer (BC) is the most common malignancy and the leading cause of cancer death among women. About 15–20% of all BCs are HER2-positive. Proper assessment of HER2 status is crucial to choose appropriate treatment. The review summarizes data on anti-HER2 drugs used t...

Full description

Bibliographic Details
Main Authors:	Martyna Zielińska, Natalia Zarankiewicz, Katarzyna Kosz, Aleksandra Kuchnicka, Bogumiła Ciseł
Format:	Article
Language:	English
Published:	Institute of Rural Health 2020-06-01
Series:	Journal of Pre-Clinical and Clinical Research
Subjects:	breast cancer targeted therapies her2-positive breast cancer her2-targeting treatment anti-her2 drugs
Online Access:	http://www.journalssystem.com/jpccr/HER2-positive-breast-cancer-Available-anti-HER2-therapies-and-new-agents-under-investigation,122068,0,2.html

Similar Items

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
by: Ismail Essadi, et al.
Published: (2023-03-01)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
by: Jing Ma, et al.
Published: (2022-07-01)

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
by: Magdalena Keller, et al.
Published: (2023-01-01)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
by: Angelica Ferrando-Díez, et al.
Published: (2022-07-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
by: Jenny Karlsson, et al.
Published: (2023-06-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
by: Chiara Tommasi, et al.
Published: (2024-03-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
by: Isabella Damiani, et al.
Published: (2021-08-01)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
by: Shuling Zhou, et al.
Published: (2023-01-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
by: Benjamin Daniels, et al.
Published: (2019-09-01)

Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy
by: S kargar, et al.
Published: (2013-10-01)

Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence
by: Kamel Debbi, et al.
Published: (2023-04-01)

Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
by: Serafin Morales, et al.
Published: (2021-11-01)

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
by: Saleh Alrhmoun, et al.
Published: (2022-12-01)

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
by: Leopoldo Sitia, et al.
Published: (2022-05-01)

Reviving a Classic Antigen with a Cutting-Edge Approach: Nanobodies for HER2+ Breast Cancer
by: Chiara Castrignano, et al.
Published: (2023-05-01)

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
by: Iain R. Macpherson, et al.
Published: (2019-12-01)

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
by: Michelle Bradbury, et al.
Published: (2023-12-01)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
by: Simon Peter Gampenrieder, et al.
Published: (2021-12-01)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
by: Lena-Christin Conradi, et al.
Published: (2019-09-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

Advances in targeted therapy for HER2-low breast cancer
by: GUO Qing, ZHANG Jian
Published: (2023-02-01)

New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
by: Essia Mezni, et al.
Published: (2020-06-01)

A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
by: Yan Yan, et al.
Published: (2021-05-01)

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
by: Manuel Gámez-Chiachio, et al.
Published: (2022-09-01)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01)

The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
by: Yingying Zhao, et al.
Published: (2024-03-01)

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
by: Marta Sanz-Álvarez, et al.
Published: (2023-12-01)

Importance of HER2/NEU (C-ERB-B2) Status in Breast Cancer: Which Method is More Effective to Evaluate of HER-2 Status?
by: Nuket Eliyatkın, et al.
Published: (2013-10-01)

HOW SHOULD BE THE SURGICAL APPROACH TO HER2 POSITIVE BREAST CANCER?
by: Can Atalay
Published: (2010-01-01)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
by: Fanfan Li, et al.
Published: (2022-03-01)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialResearch in context
by: Valentina Guarneri, et al.
Published: (2022-11-01)

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
by: Ana Godoy-Ortiz, et al.
Published: (2019-10-01)